China Infrastructure Construction has agreed to acquire Precision Research Institute, a multi-specialty medical research center offering clinical trials. Financial terms were not disclosed. “This acquisition of PRI, our second in the past year, now puts CHNC in the unique position of conducting its own clinical research trials, which holds important value to the future of Medicine. CHNC is now in a position to be the leader in the arena of Medical Clinical Trials. CHNC is in the process of becoming its very own Contract Research Organization in the Industry. The looking forward to developing the future of Pharmaceutical, Biotechnology, and Pharmacovigilance Clinical Trials. PRI has Phase I, II, and III clinical trial capabilities--a rare feat. PRI’s facility is 4500 sq ft and currently has ongoing Phase II, III clinical trials, along with observational studies. Their fifteen active multi-million-dollar contracts are a great head start for CHNC. We look forward to expanding quickly,” Elizabeth Hernandez, China Infrastructure Construction President & CEO.